Pegnivacogin

DB06293InvestigationalSmall molecule

Investigated for use/treatment in thrombosis, coronary artery disease, and vascular diseases.

Mechanism: Pharmacologically active on Coagulation factor IX
Curator reviewed
Primary indication: Investigated for use/treatment in thrombosis, coronary artery disease, and vascular diseases.Curator reviewed
Formula / weight: C₂₀H₄₀N₃O₁₁P · 529.524 g/mol (avg)
Code names: RB-006

Resolves to

Compound

Structure

InChIKeyQGVYYLZOAMMKAH-UHFFFAOYSA-NSMILESCOCCOC(=O)NCCCCC(NC(=O)OCCOC)C(=O)NCCCCCCOP(O)(O)=O

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

36Drug interactionsStructured to mechanism, not free text

2Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Pegnivacogin, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.